UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2021
Commission File Number 001-15170
GlaxoSmithKline plc
(Translation of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
GlaxoSmithKline plc (the 'Company')
Transaction notification
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dr H Barron |
| b) | Position/status | Chief Scientific Officer and President, R&D |
| c) | Initial notification/ amendment | Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GlaxoSmithKline plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
| b) | Nature of the transaction | Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $39.0300 | 2,552.047 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
| Aggregated volume Price | |
| e) | Date of the transaction | 2021-05-20 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Dr H Barron |
| b) | Position/status | Chief Scientific Officer and President, R&D |
| c) | Initial notification/ amendment | Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GlaxoSmithKline plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
| b) | Nature of the transaction | Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $39.0300 | 67 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
| Aggregated volume Price | |
| e) | Date of the transaction | 2021-05-20 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
| 1. | Details of PDMR/person closely associated with them ('PCA') |
| a) | Name | Mr J Ford |
| b) | Position/status | SVP & General Counsel |
| c) | Initial notification/ amendment | Initial notification |
| 2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
| a) | Name | GlaxoSmithKline plc |
| b) | LEI | 5493000HZTVUYLO1D793 |
| 3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted |
| a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053 |
| b) | Nature of the transaction | Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends |
| c) | Price(s) and volume(s) | | Price(s) | Volume(s) | |
| | $39.0300 | 65.537 | |
| | | | |
| d) | Aggregated information | N/A (single transaction) |
Aggregated volume Price | |
| e) | Date of the transaction | 2021-05-20 |
| f) | Place of the transaction | New York Stock Exchange (XNYS) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.
| | GlaxoSmithKline plc |
| | (Registrant) |
| | |
| Date: May 24, 2021 | |
| | |
| | By:/s/ VICTORIA WHYTE -------------------------- |
| | |
| | Victoria Whyte |
| | Authorised Signatory for and on |
| | behalf of GlaxoSmithKline plc |
